Aurora Cannabis Inc. reported record-breaking financial and operational results for the third quarter of fiscal 2025, achieving all-time highs in global medical net revenue, net income, adjusted EBITDA, and free cash flow. Total net revenue increased 37% year-over-year to $88.2 million, driven by a 51% growth in its global medical cannabis business.
Global medical cannabis net revenue reached $68.1 million, contributing 77% of Aurora's consolidated net revenue, with international net revenue growing 112% and accounting for 60% of global medical cannabis net revenue. The adjusted gross margin before fair value adjustments improved to 65%, and the medical cannabis segment's adjusted gross margin reached 74%.
Adjusted EBITDA surged 316% to $23.1 million, and the company generated positive free cash flow of $27.4 million. Concurrently, Aurora filed a preliminary base shelf prospectus to qualify the issuance of up to U.S. $250 million in various securities, providing financial flexibility for future strategic initiatives.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.